ARTV advances pivotal Phase III trial in refractory RA
A novel NK cell platform is advancing in autoimmune disease with a pivotal Phase III trial in refractory RA targeting deep B-cell depletion, citing promising early efficacy and safety.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.